Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Dividend Aristocrats Part 50: Johnson & Johnson (JNJ)

Page 1 of 3

The image below shows the 10 year cumulative returns of Johnson & Johnson (NYSE:JNJ) and the S&P 500 (SPY):

Source: Data from Yahoo! Finance

$1.00 invested in Johnson & Johnson on 1/27/2006 is worth $2.33 versus $1.82 for the same investment in SPY (both include reinvested dividends).

A large part of Johnson & Johnson’s outperformance over the last decade is because the stock fell less during the Great Recession (the red bars in the image above).

There are plenty of investments that outperformed Johnson & Johnson over the last decade – but beating the market is nothing to sneeze at.

There’s a hidden value to Johnson & Johnson stock not reflected in its return…

The company is an exceptionally low risk investment. Compare Johnson & Johnson’s stock price standard deviation to that of the S&P 500’s over the last 10 years:

– S&P 500 standard deviation of 20.7%

– Johnson & Johnson standard deviation of 16.3%

It’s true, standard deviation is not real risk, but it is a proxy for risk that is a good predictor of how easy or difficult a stock will be to hold.

The lower the standard deviation, the lower (on average) declines during recessions – and the less likely investors are to panic at the worst possible time.

Johnson & Johnson has delivered greater returns with lower risk as compared to the S&P 500 over the last decade.

That’s a claim few businesses can make.

At the same time, Johnson & Johnson is one of the most popular healthcare stocks among smart money investors. A total of 74 funds among those tracked by Insider Monkey reported long positions in the company with a total value of $3.93 billion as of the end of September, which compares to 78 investors holding stakes worth $4.38 billion in aggregate a quarter earlier. Billionaire Ken Fisher’s Fisher Asset Management held 10.69 million shares of Johnson & Johnson at the end of the third quarter.

Get To Know Johnson & Johnson

Johnson & Johnson was founded in 1886. Since that time, Johnson & Johnson has grown to become the largest health care business in the world.

The company currently has a market cap of nearly $280 billion and generated $17.4 billion in adjusted earnings in fiscal 2015.

Success is nothing new to Johnson & Johnson. The company has paid increasing dividends for 53 consecutive years.

JNJ Dividends
Source: Johnson & Johnson Pharmaceutical Presentation, slide 21

Johnson & Johnson’s long dividend history makes it 1 of 17 Dividend Kings. Dividend Kings are stocks with 50+ consecutive years of dividend increases – twice the minimum amount needed to be a Dividend Aristocrat.

Johnson & Johnson’s consistency comes from its wide diversification within the health care industry.

The company operates in 3 segments. The percentage of total sales each segment generated in fiscal 2015 is shown below:

– The consumer segment generated 19% of total sales

– The pharmaceutical segment generated 45% of total sales

– The medical devices segment generated 36% of total sales

Johnson & Johnson’s diversification within the health care industry provides the company with stable cash flows.

In addition to diversification within the health care industry, Johnson & Johnson is also well diversified globally:

– United States sales were 51% of total sales in fiscal 2015

– Europe sales were 23% of total sales in fiscal 2015

– Asia-Pacific, Africa sales were 18% of total sales in fiscal 2015

– Western Hemisphere (excluding U.S.) sales were 9% of total sales in fiscal 2015

Follow Johnson & Johnson (NYSE:JNJ)
Trade (NYSE:JNJ) Now!

Page 1 of 3

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!